Cargando…

Encapsulating Peritoneal Sclerosis in Systemic Lupus Erythematosus, Rheumatoid Arthritis, and Systemic Sclerosis

We encountered a 57-year-old Japanese woman with encapsulating peritoneal sclerosis (EPS) in systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and systemic sclerosis. The patient was admitted to our hospital because of ascites retention. Administration of tocilizumab, an anti-interleuki...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsuda, Mayumi, Yokota, Kazuhiro, Ichimura, Takaya, Sakai, Sakon, Maruyama, Takashi, Tsuzuki Wada, Takuma, Araki, Yasuto, Funakubo Asanuma, Yu, Akiyama, Yuji, Sasaki, Atsushi, Mimura, Toshihide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10293004/
https://www.ncbi.nlm.nih.gov/pubmed/36288993
http://dx.doi.org/10.2169/internalmedicine.9793-22
Descripción
Sumario:We encountered a 57-year-old Japanese woman with encapsulating peritoneal sclerosis (EPS) in systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and systemic sclerosis. The patient was admitted to our hospital because of ascites retention. Administration of tocilizumab, an anti-interleukin-6 receptor antibody, for her RA reduced the refractory ascites remarkably; however, she developed sudden acute gastrointestinal bleeding and died a year later. On autopsy, sclerotic thickening of the peritoneum showed diffuse infiltration of podoplanin-positive fibroblast-like cells, and a diagnosis of EPS was made. EPS rarely occurs in SLE, and tocilizumab may be a new treatment candidate for EPS.